ArticleJournal of biomedical research2016

The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia.

Yu Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.